Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A New Antibody-Drug Conjugate Composed of an Anti-HLA-DR IgG4 Antibody, IMMU-114, and SN-38, Is Active in Experimental Acute Myelocytic Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and Multiple Myeloma (MM)

David M Goldenberg, ScD, MD, Robert M Sharkey, Ph.D., Serengulam V Govindan, PhD, Maria Zalath, BA, Ali Mostafa, BS, Thomas M Cardillo, Ph.D.

Blood (2016) 128 (22): 3958.

https://doi.org/10.1182/blood.V128.22.3958.3958

Published: 2016

Journal Articles

Immunornase Therapy Of Lymphoma With Novel CD22-Targeting Quadruple Ranpirnase

Donglin Liu, Ph.D., Thomas M Cardillo, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2013) 122 (21): 3075.

https://doi.org/10.1182/blood.V122.21.3075.3075

Published: 2013

Journal Articles

A New Class of Hexavalent Bispecific Antibodies and Immunocytokines with Enhanced Pharmacokinetics and Improved Efficacy in Vivo .

Edmund A Rossi, Ph.D, Thomas M Cardillo, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2012) 120 (21): 2451.

https://doi.org/10.1182/blood.V120.21.2451.2451

Published: 2012

Journal Articles

Prevention of Acute Graft-Versus-Host Disease in Human/Mouse Xenogeneic SCID Mouse Model by Humanized Anti-CD74 Monoclonal Antibody, Milatuzumab

Xiaochuan Chen, Ph.D, Chien-Hsing Chang, Ph.D, Rhona Stein, Ph.D, Thomas M Cardillo, Ph.D, David V. Gold, Ph.D., David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 4105.

https://doi.org/10.1182/blood.V120.21.4105.4105

Published: 2012

Journal Articles

A Novel T-Cell Redirecting Anti-CD19-F(ab) 2 /CD3scFv Bispecific Antibody Exhibits Potent Lymphoma Cytotoxicity.

Diane L Rossi, M.S., Edmund A Rossi, Ph.D, Thomas M Cardillo, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2012) 120 (21): 2762.

https://doi.org/10.1182/blood.V120.21.2762.2762

Published: 2012

Journal Articles

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

Pankaj Gupta, David M. Goldenberg, Edmund A. Rossi, Thomas M. Cardillo, John C. Byrd, Natarajan Muthusamy, Richard R. Furman, Chien-Hsing Chang

Blood (2012) 119 (16): 3767–3778.

https://doi.org/10.1182/blood-2011-09-381988

Published: 2012

Includes: Supplemental data

Journal Articles

Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL)

Pankaj Gupta, Ph.D, David M. Goldenberg, ScD, MD, Edmund A Rossi, Ph.D, Thomas M. Cardillo, Ph.D, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D, Richard R. Furman, MD, Chien-Hsing Chang, Ph.D

Blood (2011) 118 (21): 599.

https://doi.org/10.1182/blood.V118.21.599.599

Published: 2011

Journal Articles

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers

Edmund A. Rossi, Diane L. Rossi, Thomas M. Cardillo, Rhona Stein, David M. Goldenberg, Chien-Hsing Chang

Blood (2011) 118 (7): 1877–1884.

https://doi.org/10.1182/blood-2011-03-343145

Published: 2011

Includes: Supplemental data

Journal Articles

Therapy of B-cell malignancies by anti–HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

Rhona Stein, Pankaj Gupta, Xiaochuan Chen, Thomas M. Cardillo, Richard R. Furman, Susan Chen, Chien-Hsing Chang, David M. Goldenberg

Blood (2010) 115 (25): 5180–5190.

https://doi.org/10.1182/blood-2009-06-228288

Published: 2010

Includes: Supplemental data

Journal Articles

Therapy of B-Cell Malignancies by Anti-HLA-DR Humanized Monoclonal Antibody, IMMU-114, Is Mediated through Hyperactivation of ERK and JNK MAP Kinase Signaling Pathways.

Pankaj Gupta, Ph.D, Rhona Stein, PhD, Thomas M Cardillo, PhD, Richard R Furman, Susan Chen, Chien-Hsing Chang, PhD, David M. Goldenberg, ScD, MD

Blood (2009) 114 (22): 3738.

https://doi.org/10.1182/blood.V114.22.3738.3738

Published: 2009

Journal Articles

CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomas

Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, Chien-Hsing Chang

Blood (2009) 114 (18): 3864–3871.

https://doi.org/10.1182/blood-2009-06-228890

Published: 2009

Includes: Supplemental data

Journal Articles

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma

Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, Chien-Hsing Chang

Blood (2009) 113 (24): 6161–6171.

https://doi.org/10.1182/blood-2008-10-187138

Published: 2009

Includes: Supplemental data

Journal Articles

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

David M. Goldenberg, Edmund A. Rossi, Rhona Stein, Thomas M. Cardillo, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri, Hans J. Hansen, Chien-Hsing Chang

Blood (2009) 113 (5): 1062–1070.

https://doi.org/10.1182/blood-2008-07-168146

Published: 2009

Includes: Supplemental data

Journal Articles

A Novel Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method.

Edmund A Rossi, PhD, Chien-Hsing Chang, PhD, Thomas M Cardillo, PhD, Diane L Nordstrom, David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 1590.

https://doi.org/10.1182/blood.V112.11.1590.1590

Published: 2008

Journal Articles

Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity.

Edmund A Rossi, PhD, Chien-Hsing Chang, PhD, Thomas M Cardillo, PhD, Rhona Stein, PhD, Diana Pilas, Diane L Nordstrom, John Kopinski, David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 1591.

https://doi.org/10.1182/blood.V112.11.1591.1591

Published: 2008

Journal Articles

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action

Zhengxing Qu, David M. Goldenberg, Thomas M. Cardillo, Victoria Shi, Hans J. Hansen, Chien-Hsing Chang

Blood (2008) 111 (4): 2211–2219.

https://doi.org/10.1182/blood-2007-08-110072

Published: 2008

Includes: Supplemental data

Journal Articles

A New Class of Dimeric α-Interferons (IFN-α) Made by the Dock and Lock (DNL) Method for Improved Cancer Therapy.

Edmund A. Rossi, PhD, William J. McBride, Ph.D., Diane L. Nordstrom, M.S., Preeti Trisal, M.S., Thomas M. Cardillo, Ph.D., David M. Goldenberg, M.D. Sc.D., Chien-Hsing Chang, Ph.D.

Blood (2007) 110 (11): 1396.

https://doi.org/10.1182/blood.V110.11.1396.1396

Published: 2007

Journal Articles

Recombinant Bispecific Monoclonal Antibody (bsMAb) Against CD20 and CD22 Active In Vitro and In Vivo Against B-Cell Lymphomas.

Zhengxing Qu, PhD, Thomas M. Cardillo, PhD, Victoria Shi, MSc, Diana L. Delaney, MSc, Hans J. Hansen, PhD, Chien-Hsing Chang, PhD, David M. Goldenberg, ScD,MD

Blood (2006) 108 (11): 2521.

https://doi.org/10.1182/blood.V108.11.2521.2521

Published: 2006

Journal Articles

Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies

Rhona Stein, Zhengxing Qu, Thomas M. Cardillo, Susan Chen, Adriane Rosario, Ivan D. Horak, Hans J. Hansen, David M. Goldenberg

Blood (2004) 104 (12): 3705–3711.

https://doi.org/10.1182/blood-2004-03-0890

Published: 2004

Journal Articles

In Vitro and In Vivo Targeting and Therapy of an Antibody-Drug Conjugate (IMMU-110) in B-Cell Malignancies.

Puja Sapra, PhD, Rhona Stein, PhD, Jennifer Pickett, PhD, Serengulam V. Govindan, PhD, Thomas M. Cardillo, PhD, Christopher Damoci, BS, Agatha Sheerin, BS, Hans J. Hansen, PhD, Ivan D. Horak, MD, Gary L. Griffiths, PhD, David M. Goldenberg, ScD, MD

Blood (2004) 104 (11): 3287.

https://doi.org/10.1182/blood.V104.11.3287.3287

Published: 2004

NARROW

A New Antibody-Drug Conjugate Composed of an Anti-HLA-DR IgG4 Antibody, IMMU-114, and SN-38, Is Active in Experimental Acute Myelocytic Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and Multiple Myeloma (MM)

Immunornase Therapy Of Lymphoma With Novel CD22-Targeting Quadruple Ranpirnase

A New Class of Hexavalent Bispecific Antibodies and Immunocytokines with Enhanced Pharmacokinetics and Improved Efficacy in Vivo .

Prevention of Acute Graft-Versus-Host Disease in Human/Mouse Xenogeneic SCID Mouse Model by Humanized Anti-CD74 Monoclonal Antibody, Milatuzumab

A Novel T-Cell Redirecting Anti-CD19-F(ab) 2 /CD3scFv Bispecific Antibody Exhibits Potent Lymphoma Cytotoxicity.

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL)

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers

Therapy of B-cell malignancies by anti–HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

Therapy of B-Cell Malignancies by Anti-HLA-DR Humanized Monoclonal Antibody, IMMU-114, Is Mediated through Hyperactivation of ERK and JNK MAP Kinase Signaling Pathways.

CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomas

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

A Novel Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method.

Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity.

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action

A New Class of Dimeric α-Interferons (IFN-α) Made by the Dock and Lock (DNL) Method for Improved Cancer Therapy.

Recombinant Bispecific Monoclonal Antibody (bsMAb) Against CD20 and CD22 Active In Vitro and In Vivo Against B-Cell Lymphomas.

Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies

In Vitro and In Vivo Targeting and Therapy of an Antibody-Drug Conjugate (IMMU-110) in B-Cell Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only